Press Releases
QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, today announced its preliminary, unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. For the full year 2024, the Company recorded record revenue growth, substantial gross margin improvements, its first-ever year of profitability on a GAAP basis and positive cash flow from operations, which enabled it to repay a portion of its outstanding debt strengthening its balance sheet.
QHSLab Inc. ("the Company") (OTCQB: USAQ), an emerging leader in digital healthcare solutions and value-based clinical technologies, today proudly announces significant milestones that underscore its progress in 2024. These accomplishments demonstrate the Company’s commitment to advancing patient care, driving innovation, and delivering value to shareholders.
QHSLab Inc. ("the Company") (OTCQB: USAQ), a leader in digital healthcare and point-of-care technologies designed to empower clinicians with proactive value-based healthcare solutions, today announced detailed financial results for the second quarter and six months ended June 30, 2024. The Company’s Integrated Service Program (ISP) has driven robust revenue growth and improved gross margins, while the Company focused on effective cost management and enhanced cash flow management.
QHSLab released detailed financial results for the first quarter ended March 31, 2024, showcasing not only revenue growth but also significant reductions in operating expenses and a positive turn in net operating income.
QHSLab, Inc. ("the Company") (OTCQB: USAQ), a leader in digital health and point-of-care technologies designed to empower clinicians with proactive, value-based healthcare solutions, today announced its preliminary unaudited revenue for the first quarter ended March 31, 2024.
QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, today reported its financial and operational results for the fiscal year ended December 31, 2023. The year was marked by robust revenue growth, significant improvements in gross margins, and a strategic focus on expanding product lines and the Company’s customer base.
QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update. In the first nine months of this year, QHSLab conducted over 30,000 digital medicine assessments through healthcare providers, encompassing mental health evaluations, allergy and asthma assessments, psychological screenings, chronic pain monitoring, and more.
QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, is proud to announce that since the start of Q4 2023 it has gained six new multi-location customer accounts for its Integrated Service Program (ISP) in South Florida.
QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, is proud to announce a series of accomplishments year-to-date (YTD) demonstrating the company's commitment to transforming patient care through technology and innovation.
As the allergy crisis continues to rise, more than sixty million Americans suffer from an allergic disease. Approximately 47% of American adults have some form of hypertension, and less than half of those individuals have their blood pressure under control. We know that stress levels among members of modern American society are higher than ever.
The challenges primary care physicians face extend beyond just the shortage. These healthcare professionals shoulder an average of $200,000 in medical school debt and are often overwhelmed by patient demand, leading to physician burnout. In these trying times, they need practical tools and support to continue delivering quality patient care while maintaining their practices with a growing revenue source.
While many are skeptical about the future of AI, it's undeniable that it's revolutionizing the healthcare industry. Forbes Tech Council recently published "10 Ways AI Is Advancing Healthcare." Based on this article, QHSLab is a "perfect 10" for improving clinical outcomes and increasing practice revenue for healthcare providers.
Healthcare providers are acutely aware of the impact of physical and mental health conditions on patients. While the connection between allergies and depression may seem unexpected, recent research underscores the importance of understanding this relationship. Moreover, we recognize that comprehensive screenings, such as those provided by QHSLab, are essential in assessing allergy baseline and mental health conditions like depression using tools such as the PHQ-GAD16 and Q-Scale.
In today's fast-paced world, mental health has emerged as a critical concern, with conditions like depression and anxiety negatively impacting multiples of millions of Americans. Surprisingly, many struggling with mental illness do not seek the help they need, often avoiding routine annual wellness visits (AWV) altogether. However, research shows that integrating regular depression and anxiety screenings into check-ups can be a game-changer in identifying and addressing these issues. Your patient's mental health is as vital as measuring blood pressure, body weight, and temperature, and assessing mental well-being has become increasingly crucial for maintaining overall health.
As the back-to-school season approaches, excitement and anticipation sweep over children, college students - and their parents alike. However, this transitional period can also trigger significant anxiety for many individuals. Here's how QHSLab's cutting-edge mental health assessments and interventions, including the PHQ9-GAD7 and the Q-Scale, are helping physicians address and manage these concerns.
At QHSLab, we believe that comprehensive patient care starts with accurate and efficient assessments. By utilizing the PHQ-GAD16, you can identify patients who may require further evaluation, counseling, or referral to mental health professionals. Additionally, you can tailor treatment plans based on each patient’s needs, improving patient outcomes and satisfaction.
QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, today announced its first-quarter financial results for the period ended March 31, 2023, reporting strong sequential growth and setting expectations for the remainder of fiscal 2023.
Physical activity should be a mainstay approach in managing depression, anxiety, and psychological distress. There has been a significant gap in comprehensive tools designed to meet the growing demands placed on primary care providers - until QHSLab.
QHSLab, Inc. (QHSLab) and Healthcare Information Technology Specialists, LLC (HIT) entered into a representation agreement, enabling HIT to recruit its medical office and physician clients to contract with the QHSLab digital healthcare platform.
QHSLab reports that commercialization and the path to profitability is in clear sight, which is an unfamiliar acknowledgment for investors focused on the digital health community, many of which are currently witnessing poor outcomes from their previous investments. Multiple digital health companies have shed millions without creating a revenue stream. QHSLab is an alternative for investors to refocus and recoup on these underperforming companies.
A recent survey published in a report in Healthcare Finance News states that "nearly four in five Americans said that virtual primary care has allowed them to take charge of their health." While digital health and telehealth services have been making strides in the medical industry for some time, the COVID-19 pandemic has accelerated their adoption by both providers and patients - streamlining the physician's workflow and increasing the value of healthcare for patients.
This forecast is based on estimates generated through a recent pilot program and scaled through approximately 250,000 independent primary care practitioners in the United States. National reports indicate that there are over 500 million healthcare patient encounters per year. 52% of all physician office visits are in primary care. QHSLab is poised to become the premier digital health tool addressing specific preventive and chronic care gaps for family and pediatric primary care, especially for the independent and solo provider.
The screenings are being recommended as pediatric mental health concerns are at alarming levels. The COVID-19 pandemic has left an indelible mark on the healthcare landscape. A byproduct of the pandemic is a major need for population based mental health screenings in all primary care and pediatric settings. Presentation of mental health concerns is now at an all-time high, especially among children and adolescents.
The latest recommendations from the U.S. Preventive Services Task Force (USPSTF) indicate that all adults under the age of 65 be screened for anxiety and depression in primary care including children and adolescents aged 8 to 18 years should also be regularly screened.
QHSLab, Inc. is leading the way in assisting independent practices to embrace reimbursable non-face-to-face digital health tools for efficient clinical decision support and patient care coordination.
QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point of care technologies, today announced the launch of its proprietary Post-COVID Condition Health Habits digital health tool for screening primary care patients potentially suffering from a “long COVID” or “post-COVID” conditions.
QHSLab, Inc. (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging point of care technologies, today announced a strategic alliance with Medical License Factory, LLC, a prominent physician licensing and management services organization, for its AllergiEnd® allergy diagnostic and allergen immunotherapy products and clinical decision support digital health services.
Recent headlines undoubtedly caused concern for investors across all industries. However, at QHSLab, Inc., we are confident in our ability to weather the market volatility with our sound fundamental point of care and digital healthcare business focus. Since our inception we have been focused on achieving earnings and positive cash flow and have steadily moved towards those goals. Despite these challenging times, we have been generating growing revenue over the past six quarters and see continuing progress, while keeping our expenses down.
The delivery of healthcare is changing. The recent HIMSS State of Healthcare summit in Orlando, Florida, highlights the changing landscape since the onset of the COVID pandemic in 2020. The key takeaway stated succinctly by a panelist is this: "[Digital transformation] is no longer an option; it's a mandate.” Now more than ever, patients are demanding comprehensive care for their investment in healthcare. With insurance premiums and deductibles at all-time highs, value and positive peer reviews are some of the most critical points of consideration when deciding to book an appointment with a provider. In addition, referrals are crucial for sustaining practices, and there's no better referral than word-of-mouth.
QHSLab, Inc. (OTCQB: USAQ) a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging point of care technologies, projects a new $90 million annual addressable market for the Company’s latest product, the Allergy Quick Test, branded AllergiQT™.